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Abstract
Objectives The aim of this study is to assess the levels and
diagnostic accuracy of a set of bone resorption biomarkers,
including TRAP-5, RANKL, and OPG in symptomatic and
asymptomatic apical lesions and controls.
Materials and methods Apical tissues from symptomatic and
asymptomatic apical periodontitis patients and periodontal
ligaments from healthy teeth extracted for orthodontic reasons
were processed for tissue homogenization and the levels of
TRAP-5, RANKL, and OPG were determined by multiplex
assay. Marker levels were analyzed by Kruskal Wallis test,
and diagnostic accuracy was analyzed with ROC curves.
Results Higher levels of RANKL, OPG, and RANKL/OPG
ratio were determined in both types of apical lesions compared
to healthy periodontal ligament, whereas higher TRAP-5
levels were found only in symptomatic apical lesions
(p < 0.05). OPG, RANKL, and RANKL/OPG ratio showed
diagnostic potential to identify apical lesions versus healthy
controls (AUC = 0.69, p < 0.05); while TRAP-5 showed a
potential to discriminate symptomatic versus asymptomatic
apical periodontitis (AUC = 0.71, p < 0.05) and healthy con-
trols (AUC = 0.83, p < 0.05).
Conclusions Apical lesions showed higher RANKL and OPG
levels than healthy tissues. TRAP-5 levels were the highest in
symptomatic apical lesions, suggesting that these represent a
progressive state, and showed diagnostic potential.
Clinical relevance Clinically symptomatic apical periodonti-
tis might represent biologically progressive apical lesions
based on TRAP5 levels. TRAP5 has diagnostic potential to
identify these lesions, representing a candidate prognostic
biomarker.
Keywords Symptomatic . Asymptomatic periapical
periodontitis . Bone resorption . Biomarkers . TRAP .
RANKL . OPG
Introduction
Apical periodontitis originates from host’s immune response
to a dominant Gram-negative anaerobic biofilm localized in-
side the root canal system of the tooth and their respective by-
products. Given the inability to eliminate bacteria, the host
attempts to localize the infection and prevent further dissem-
ination at the expense of apical tissue breakdown that results
in the formation of an osteolytic apical lesion (AL), the hall-
mark of chronic forms of apical periodontitis [1].
AL is heterogeneous from a clinical point of view depend-
ing on its association with clinical symptoms, being either
symptomatic apical periodontitis (SAP) or asymptomatic api-
cal periodontitis (AAP) [2]. This clinical variability is expect-
ed to depend on the dynamic balance between bacterial con-
sortia and the host’s response [3–5]. Recent studies support
that symptomatic apical periodontitis associates with changes
in bacterial load and diversity [4], as well as host’s immune
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response, involving interleukin (IL)-1, IL-6, tumor necrosis
factor (TNF)-α, and matrix metalloproteinase (MMP)-9, re-
spectively [6–8]. Although the clinical diagnosis of symptom-
atic apical periodontitis is straightforward, its biologic signif-
icance remains to be known.
Osteoclasts are the final cellular effectors of bone resorp-
tion, determining progression versus healing processes in AL.
Osteoclast differentiation and activation from its monocytic
precursors is regulated in part through the balance between
the receptor activator of nuclear factor κB (RANK), its ligand
(RANKL), and its decoy receptor, osteoprotegerin (OPG).
Accordingly, significantly higher RANKL levels have been
reported in AL compared with healthy tissues [9]. RANKL/
OPG ratio has also been proposed as an indicator of AL pro-
gression [10, 11]. Tartrate-resistant acid phosphatase (TRAP)-
5 on the other hand, is an enzyme released along with bone
matrix degradation products by active osteoclasts,
representing a direct biomarker of osteoclastic activity and
bone resorption [12–17].
Higher levels of TRAP-5 are associated with the progres-
sion of bone destructive diseases; there is a current need to
identify biomarkers for AL progression [18]; however, up to
now there are no clinical studies linking TRAP-5 with apical
periodontitis [19, 20]. Furthermore, bone resorptive dynamics
in symptomatic and asymptomatic states of apical periodonti-
tis remain unknown [7]. We aimed to assess the levels and
diagnostic accuracy of a set of bone resorption biomarkers in
AL from patients with clinical diagnoses of SAP, AAP, and




Tris-HCl pH 7.5, NaCl, CaCl2, and Triton X-100 were pur-
chased from Sigma-Aldrich (St Louis, MO, USA) for homog-
enization buffer preparation. EDTA-free proteinase inhibitor
cocktail was purchased from Roche Diagnostics GmbH
(Mannheim, Germany). A Milliplex MAP multiplex assay
panel (human cancer/metastasis biomarker magnetic bead)
and human bone RANKL single-plex panel was obtained
from Millipore, Merck KGaA (Darmstadt, Germany).
Methods
Patients who consulted at the Clinic of Oral Surgery, School of
Dentistry, University of Chile, Santiago, Chile, were enrolled
if they had a clinical diagnosis of either SAP or AAP in the
presence of an apical lesion detected by apical radiography
(>2 mm diameter) caused by dental caries in teeth with a
clinical diagnosis of nonvital pulp, according to previously
defined criteria [3]. Periodontal ligaments obtained from
healthy premolars extracted for orthodontic reasons were used
as controls as previously described [21, 22]. Exclusion criteria
included systemic illness or previous antibiotics or nonsteroi-
dal anti-inflammatory treatment during a 6-months period be-
fore the study [23]. All procedures were performed in accor-
dance with the ethical standards of the institutional research
and ethics committee and with the Helsinki declaration. The
investigation protocol was clearly explained to all the partic-
ipants of this study. Each participant signed an informed con-
sent or corresponding forms for their legal guardians in case of
underage patients after the risks and benefits of participation
were described. A total of 52 apical lesions from patients with
SAP (n = 17) and AAP (n = 35), and periodontal ligament
samples from healthy volunteers (n = 24) were obtained. After
tooth extraction, apical lesions and healthy periodontal liga-
ments were extracted by surgical separation from the tooth
surface with curettes and then stored at −20 °C until processed
for tissue homogenization and multiplex assay.
Tissue homogenates and multiplex assay
After thawing, tissue samples from AL (n = 52) and control
periodontal ligaments (n = 24) were weighted. Protein extracts
were obtained by manual homogenization in 50 mMTris-HCl
pH 7.5, 0.2 mMNaCl, 5 mMCaCl2, and 0.01% Triton X-100
(Sigma-Aldrich, St Louis, MO) buffer adding EDTA-free pro-
teinase inhibitor cocktail (Roche Diagnostics GmbH,
Mannheim, Germany) in a constant ratio of 10:1 μL of buffer
per milligram of weighted tissue; centrifuged at 10,000×g for
6 min at 4 °C and stored at −80 °C until further analysis with
Milliplex MAP multiplex assays (human cancer/metastasis
biomarker magnetic bead and human bone RANKL single-
plex panels, Millipore, Merck KGaA, Darmstadt, Germany),
according to the manufacturer’s instructions. Data was read
through a Luminex platform (Magpix, Millipore, St Charles,
MO, USA), and analyzed with the MILLIPLEX AnalystR
software (ViageneTech, Carlisle, MA, USA).
Statistical analyses
Comparisons of TRAP-5, RANKL, and OPG levels between
SAP and AAP and controls were analyzed with ANOVA or
Kruskal Wallis test using STATA V.11 (StataCorp, College
Station, TX, USA), according to data distribution. The evalu-
ation of the diagnostic accuracy of the biomarkers was per-
formed through the construction of ROC curves using
SPSS19 software (IBM® Company, Armork, NY, USA) by
calculating the area under the curve (AUC). The optimal cut-
off points to estimate the highest sensitivity and specificity
altogether were assessed by Youden’s index. A p value
<0.05 was considered statistically significant.
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Results
Controls, asymptomatic apical periodontitis and symptom-
atic apical periodontitis groups had a mean age of 13.7,
50.1, and 46.5 years and 7, 12, and 11 were women, respec-
tively. No smokers were reported in the controls, whereas
there were six smokers in each apical periodontitis group.
Regarding biomarker levels (Fig. 1), significantly higher
levels of TRAP-5 were observed in SAP in comparison to
AAP and healthy controls (p < 0.05), and with no differ-
ences between the latter two groups. The levels of RANKL,
OPG, and the RANKL/OPG ratio were significantly higher
in AAP and SAP groups compared with healthy controls
(p < 0.05), and no differences were found between both
apical periodontitis groups.
The diagnostic performance of biomarkers is illustrated
with ROC curves (Fig. 2a, b, c) and their respective values
are presented in Table 1a, b, c. RANKL, OPG, and RANKL/
OPG demonstrated statistically significant (p < 0.05) diagnos-
tic accuracy to identify AAP versus healthy controls, where
the highest performance corresponded to RANKL (area
under the curve =0.77, 95% CI 0.65–0.89), [Fig. 2a and
Table 1a ]. Optimal cut-off points were obtained for each
marker by using Youden’s index. OPG showed the best per-
formance, with a sensitivity of 80% and a specificity of 69%
at a cut-off point of 50 pg/mL, followed by RANKL and
RANKL/OPG ratio.
In the construction of ROC curves for the diagnosis of
SAP versus healthy controls [Fig. 2b and Table 1b], TRAP-
5 (AUC = 0.83, 95% CI 0.68–0.98), and RANKL
(AUC = 0.83, 95% CI 0.71–0.95) were the markers with
the highest accuracy, followed by RANKL/OPG ratio and
OPG (p < 0.05). According to Youden’s index, TRAP-5
showed a sensitivity of 71%, a specificity of 100%, at a
cut-off point of 12.48 ng/mL, followed by RANKL with a
sensitivity of 77% and a specificity of 69% at a cut-off
point of 90.64 pg/mL.
TRAP-5 (AUC = 0.71, 95% CI 0.54–0.89) was the only
biomarker that showed potential to discriminate between SAP
and AAP [Fig. 2c) and Table 1c, p < 0.05]. TRAP-5 showed a
sensitivity of 73% and a specificity of 80% at a cut-off point of
12.54 ng/mL.
Fig. 1 Bone resorption biomarkers levels in healthy controls, AAP and
SAP. Control: healthy periodontal ligaments; AAP asymptomatic apical
periodontitis; SAP symptomatic apical periodontitis; TRAP5 tartrate-
resistant acid phosphatase-5; RANKL receptor activator for nuclear factor
κB ligand; OPG osteoprotegerin; RANKL/OPG ratio between RANKL
and OPG. Bars and asterisks represent significant (p < 0.05) pairwise
comparisons (ANOVA and Tukey test for TRAP-5 and Kruskal Wallis
test for RANKL, OPG, and RANKL/OPG ratio)
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Discussion
AL results from an imbalanced osteoclastic activity induced
by the immuno-inflammatory response to endodontic bacteri-
al infection [24]. Clinically symptomatic ALs have been sug-
gested to represent an immunologically active stage of the
disease [7, 8], but up to now, bone resorptive activity had
not been established. In the present study, we assessed the
levels of bone resorption markers in symptomatic and asymp-
tomatic AL and healthy periodontal ligament as controls and
found statistically significant higher levels of RANKL and
OPG in both types of apical lesions compared to healthy peri-
odontal ligament, while higher TRAP-5 levels were found
only in symptomatic AL, suggesting that the later represent
progressive lesions. TRAP-5 had diagnostic potential for SAP,
representing a potentially useful candidate biomarker for apical
periodontitis progression.
Bone resorpt ion is a mult is tep process where
RANK/RANKL/OPG pathway and TRAP-5 play key roles.
Through binding RANK, RANKL is among the key
osteolytic cytokines that promote osteoclast maturation and
activation. OPG on the other hand, is a decoy receptor that
prevents the coupling of RANK to RANKL [10]. Unlike the
RANKL/RANK axis, which might either result or not in os-
teoclast differentiation depending on the OPG levels, TRAP-5
is an enzyme released along with bone matrix degradation
products by active osteoclasts representing a direct biomarker
of osteoclastic activity and bone resorption [12–14, 19, 20].
Fig. 2 ROC curves for the diagnosis of AAP versus controls (a), SAP
versus controls (b), and AAP versus SAP (c). AAP asymptomatic apical
periodontitis; SAP symptomatic apical periodontitis; y axis: sensitivity, x
axis: 1-specificity. Lines: blue tartrate-resistant acid phosphatase-5
(TRAP), green receptor activator for nuclear factor κB ligand
(RANKL), gray osteoprotegerin (OPG), purple ratio between RANKL,
and OPG, yellow reference line
Table 1 Accuracy of biological
markers for the diagnosis of AA
versus controls (a), SAP versus
controls (b) and AAP versus SAP
(c)
Biomarker Cut-off Sensitivity Specificity Accuracy (AUC, CI) p
(a)
TRAP-5 8.45 ng/mL 0.57 0.58 0.61 (0.47–0.75) 0.143
RANKL 122.00 pg/mL 0.66 0.85 0.77 (0.65–0.89) <0.0001
OPG 50.0 pg/mL 0.80 0.69 0.82 (0.71–0.93) <0.0001
RANKL/OPG 1.05 0.69 0.66 0.70 (0.57–0.83) 0.009
(b)
TRAP-5 12.48 ng/mL 0.71 1.00 0.83 (0.68–0.98) <0.0001
RANKL 90.64 pg/mL 0.77 0.69 0.83 (0.71–0.95) <0.0001
OPG 51.50 pg/mL 0.59 0.69 0.69 (0.53–0.86) 0.035
RANKL/OPG 0.99 0.94 0.65 0.82 (0.70–0.95) <0.0001
(c)
TRAP-5 12.54 ng/mL 0.73 0.80 0.71 (0.54–0.89) 0.017
RANKL 170.5 pg/mL 0.53 0.57 0.51 (0.34–0.68) 0.92
OPG 70.50 pg/mL 0.40 0.60 0.35 (0.16–0.54) 0.10
RANKL/OPG 2.40 0.73 0.51 0.61 (0.45–0.77) 0.22
AAP asymptomatic apical periodontitis; SAP symptomatic apical periodontitis; AUC area under the curve; CI
confidence interval of 95%; TRAP5 tartrate-resistant acid phosphatase-5; RANKL receptor activator for nuclear
factor κB ligand; OPG osteoprotegerin; RANKL/OPG ratio between RANKL and OPG
p<0.05
Clin Oral Invest
In the present study the levels of RANKL, OPG and
RANKL/OPG ratio were significantly higher in symptomatic
and asymptomatic apical lesions versus healthy controls,
whereas no significant differences were found between both
lesion types. Previous reports associate high levels of RANKL
and OPG with apical lesions [10, 17, 25]. In line with our
results, a recent report showed no differences in RANKL
and OPG levels between asymptomatic and symptomatic api-
cal lesions, whereas a significantly higher number of gram-
negative bacteria along with a positive correlation with OPG
were found in the later [26]. Whereas the participants showed
an homogeneous distribution by gender, an intrinsic
methodologic drawback for including healthy periodontal lig-
ament as controls is the age difference among healthy and AP
groups, although it represents the closest histophysiologic
counterpart for ALs in humans [22]. Accordingly, higher
mRNA expression levels were found for RANKL and OPG
in apical granulomas versus periodontal ligaments [10].
Recently, RANKL was identified at higher levels in apical
exudates from asymptomatic apical periodontitis compared
to irreversible pulpitis, whereas OPG levels remained mostly
undetectable [27]. So far, there are no previous studies that
associate the RANKL/OPG levels with the clinical status in
AP. The increased levels of RANKL, OPG, and RANKL/
OPG ratio in ALs suggest that these lesions display an imbal-
ance towards osteoclast differentiation, though it might not
necessarily result in higher osteolysis [10, 27]. Based on our
results, these markers did not differentiate between symptom-
atic and asymptomatic apical lesions.
TRAP-5 levels were significantly higher in symptomatic
apical lesions compared with asymptomatic lesions and
healthy controls, while no differences were found between
asymptomatic lesions and controls. TRAP-5 has been pro-
posed to be the most reliable marker of bone resorptive activ-
ity. Clinical studies, as well as animal and in vitro experimen-
tal models, demonstrate that elevated levels of TRAP-5 can be
more specifically explained by an increase in the activity of
osteoclasts [12–15, 28]. Accordingly, studies conducted in
animal models demonstrate that bone resorption rate is signif-
icantly higher during the acute stage of apical periodontitis,
compared to its chronic phase, where it becomes slower to
finally achieve stabilization [29].
Bone resorption and RANKL production by several cell
types is synergistically induced by IL-1, IL-6, and TNF-α. In
line with our results, clinical studies report significantly higher
levels of these cytokines in apical lesions versus pulp tissue
controls and symptomatic versus asymptomatic apical lesions
[7, 8, 23]. Despite the RANKL/OPG ratio has been proposed as
an indicator of progression or stability of asymptomatic lesions
[10], osteolytic cytokines are redundant. TNF-α and IL-1 can
also stimulate osteoclast differentiation via RANKL/RANK-
independent mechanisms [30, 31], implicating that osteoclas-
togenesis is only partially accounted by the RANKL/RANK
axis. Altogether, these antecedents suggest that inflammation
enhances osteoclast differentiation in periapical lesions via
RANKL/OPG, but only symptomatic lesions might truly rep-
resent an active stage, as reflected by concomitantly elevated
RANKL/OPG ratio and TRAP-5 levels. Based on previous
reports, it is possible that activation pathways other than
RANKL might be induced in symptomatic lesions, resulting
in exacerbated bone resorption. The detection of RANKL,
OPG, and TRAP at lower levels in healthy periodontal liga-
ment on the other hand might reflect bone homeostasis.
The diagnostic accuracy of OPG, RANKL, and RANKL/
OPG ratio showed potential to identify apical lesions versus
healthy controls, but failed to discriminate between AAP and
SAP. Thus, OPG and RANKL could be useful in the diagnosis
of apical periodontitis; however, they do not differentiate be-
tween its clinical forms. TRAP-5 on the other hand proved to
have the highest diagnostic accuracy to discriminate SAP
from AAP and healthy controls, presenting potential as a
marker for progressive lesions. Accordingly, TRAP levels al-
so demonstrated diagnostic precision to identify marginal
chronic periodontitis in a recent study [15]. Currently, apical
diagnosis is based solely on clinical and radiological parame-
ters, but they fail to predict treatment outcome in the short
term. Thus, TRAP-5 screening in a noninvasive approach
might have potential as biomarker for progressive AL to aid
clinical decisions in endodontic and restorative procedures in
oral fluid samples, such as gingival crevicular fluid, saliva, or
in apical exudates during endodontic treatment [15, 32]. In
fact, TRAP levels have already shown a good performance
to identify chronic periodontitis in gingival crevicular fluid
[15]. Future prospective studies are needed to assess its use-
fulness as a predictive marker.
Conclusions
Apical lesions showed higher RANKL and OPG levels than
healthy tissues and TRAP-5 levels were the highest in symp-
tomatic apical lesions, suggesting that the later represents a
progressive disease state that can be identified by TRAP-5.
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